Market Overview

UPDATE: Stifel Nicolaus Downgrades Zogenix to Hold Following FDA Panel

Related ZGNX
Zogenix Reports Zohydro ER Shows Sustained 12-Hour Pain Relief
Zohydro Gains Massachusetts Approval, Acts As Minor Catalyst For Zogenix

Stifel Nicolaus reduced its rating on Zogenix (NASDAQ: ZGNX) from Buy to Hold and removed its $6 price target.

Stifel Nicolaus said, "The FDA Advisory Committee for Zohydro ER (single-entity hydrocodone for moderate-severe chronic pain) voted 11-2 (one abstention) against approval, highlighting concern about the opioid abuse epidemic by adding yet another non tamper-resistant, high-dose opioid. … [I]ncomplete information about how to limit the addressable population, concern regarding REMS implementation, and lack of tamper-resistance were key sticking points. Although FDA may still approve Zohydro given its legal/regulatory mandate (PDUFA 3/1/13), we are downgrading Zogenix given increased risk on its key growth driver."

Zogenix closed at $2.36 on Friday.

Latest Ratings for ZGNX

DateFirmActionFromTo
Aug 2014OppenheimerMaintainsOutperform
Jul 2014Stifel NicolausMaintainsBuy
Jun 2014RF Lafferty & Co.Initiates Coverage onBuy

View More Analyst Ratings for ZGNX
View the Latest Analyst Ratings

Posted-In: Stifel NicolausAnalyst Color Downgrades Intraday Update Analyst Ratings

 

Related Articles (ZGNX)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters